Edgewise closes $1.55B sale of sevasemten to Servier; pivots to cardiovascular pipeline

Edgewise Therapeutics, Inc.

Received $1.55B upfront cash; eligible for up to $1.1B in regulatory/commercial milestones.
Pro forma cash at March 31, 2026: $1.53B (up from $33.2M historical).
Pro forma net income for FY2025: $1.1355B (vs. historical net loss of $167.8M).
Company now focused on cardiovascular assets EDG-7500, EDG-15400, and EDG-003.
Transition Services Agreement with Servier: at least 18 months; $17.9M deferred liability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.